212 related articles for article (PubMed ID: 7535804)
1. Cytokeratin intermediate filament expression in benign and malignant breast disease.
Heatley M; Maxwell P; Whiteside C; Toner P
J Clin Pathol; 1995 Jan; 48(1):26-32. PubMed ID: 7535804
[TBL] [Abstract][Full Text] [Related]
2. Coexpression patterns of vimentin and glial filament protein with cytokeratins in the normal, hyperplastic, and neoplastic breast.
Gould VE; Koukoulis GK; Jansson DS; Nagle RB; Franke WW; Moll R
Am J Pathol; 1990 Nov; 137(5):1143-55. PubMed ID: 1700618
[TBL] [Abstract][Full Text] [Related]
3. Vimentin expression in benign and malignant breast epithelium.
Heatley M; Whiteside C; Maxwell P; Toner P
J Clin Pathol; 1993 May; 46(5):441-5. PubMed ID: 7686566
[TBL] [Abstract][Full Text] [Related]
4. Double immunolabeling with cytokeratin and smooth-muscle actin in confirming early invasive carcinoma of breast.
Prasad ML; Hyjek E; Giri DD; Ying L; O'Leary JJ; Hoda SA
Am J Surg Pathol; 1999 Feb; 23(2):176-81. PubMed ID: 9989844
[TBL] [Abstract][Full Text] [Related]
5. Differential diagnosis of benign epithelial proliferations and carcinomas of the breast using antibodies to cytokeratins.
Jarasch ED; Nagle RB; Kaufmann M; Maurer C; Böcker WJ
Hum Pathol; 1988 Mar; 19(3):276-89. PubMed ID: 2450059
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain.
Werling RW; Hwang H; Yaziji H; Gown AM
Am J Surg Pathol; 2003 Jan; 27(1):82-90. PubMed ID: 12502930
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the patterns of laminin expression in fibroadenoma, fibrocystic diseases, pre-invasive and invasive ductal breast carcinoma.
Zheng WQ; Looi LM; Cheah PL
Pathology; 2001 Aug; 33(3):303-6. PubMed ID: 11523929
[TBL] [Abstract][Full Text] [Related]
8. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas.
Malzahn K; Mitze M; Thoenes M; Moll R
Virchows Arch; 1998 Aug; 433(2):119-29. PubMed ID: 9737789
[TBL] [Abstract][Full Text] [Related]
9. Expression of c-kit in common benign and malignant breast lesions.
Kondi-Pafiti A; Arkadopoulos N; Gennatas C; Michalaki V; Frangou-Plegmenou M; Chatzipantelis P
Tumori; 2010; 96(6):978-84. PubMed ID: 21388062
[TBL] [Abstract][Full Text] [Related]
10. Cytokeratins 7 and 14 in special types of invasive breast carcinomas.
Toth T
Med Pregl; 1999; 52(6-8):227-32. PubMed ID: 10518377
[TBL] [Abstract][Full Text] [Related]
11. Co-expression of cytokeratin and vimentin intermediate filament proteins in benign and neoplastic breast epithelium.
Raymond WA; Leong AS
J Pathol; 1989 Apr; 157(4):299-306. PubMed ID: 2469782
[TBL] [Abstract][Full Text] [Related]
12. Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions.
Yu BH; Tang SX; Xu XL; Cheng YF; Bi R; Shui RH; Tu XY; Lu HF; Zhou XY; Yang WT
J Clin Pathol; 2018 Jun; 71(6):546-553. PubMed ID: 29436376
[TBL] [Abstract][Full Text] [Related]
13. Structural distinctions among human breast epithelial cells revealed by the monclonal antikeratin antibodies AE1 and AE3.
Sorenson SC; Asch BB; Connolly JL; Burstein NA; Asch HL
J Pathol; 1987 Oct; 153(2):151-62. PubMed ID: 2447254
[TBL] [Abstract][Full Text] [Related]
14. Histopathology of myoepithelial (basocellular) hyperplasias in adenosis and epitheliosis of the breast demonstrated by the reactivity of cytokeratins and S100 protein. An analysis of heterogenic cell proliferations in 90 cases of benign and malignant breast diseases.
Bässler R; Katzer B
Virchows Arch A Pathol Anat Histopathol; 1992; 421(5):435-42. PubMed ID: 1280883
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor immunohistochemistry in different histological types of infiltrating breast carcinoma.
Martinazzi M; Crivelli F; Zampatti C; Martinazzi S
J Clin Pathol; 1993 Nov; 46(11):1009-10. PubMed ID: 8254086
[TBL] [Abstract][Full Text] [Related]
16. High expression of the antigen recognized by the monoclonal antibody GB24 on human breast carcinomas: a preventive mechanism of malignant tumor cells against complement attack?
Hofman P; Hsi BL; Manie S; Fenichel P; Thyss A; Rossi B
Breast Cancer Res Treat; 1994; 32(2):213-9. PubMed ID: 7532466
[TBL] [Abstract][Full Text] [Related]
17. CD24 is a marker for human breast carcinoma.
Fogel M; Friederichs J; Zeller Y; Husar M; Smirnov A; Roitman L; Altevogt P; Sthoeger ZM
Cancer Lett; 1999 Aug; 143(1):87-94. PubMed ID: 10465342
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of keratins 13 and 16 in normal epithelium, benign lesions, and ductal carcinomas of the human breast determined by the monoclonal antibody Ks8.12.
Pellegrino MB; Asch BB; Connolly JL; Asch HL
Cancer Res; 1988 Oct; 48(20):5831-6. PubMed ID: 2458830
[TBL] [Abstract][Full Text] [Related]
19. Keratin polypeptide distribution in benign and malignant breast tumors: subdivision of ductal carcinomas using monoclonal antibodies.
Altmannsberger M; Dirk T; Droese M; Weber K; Osborn M
Virchows Arch B Cell Pathol Incl Mol Pathol; 1986; 51(3):265-75. PubMed ID: 2874659
[TBL] [Abstract][Full Text] [Related]
20. Malignant myoepithelioma (myoepithelial carcinoma) of the breast: a detailed cytokeratin study.
Lakhani SR; O'Hare MJ; Monaghan P; Winehouse J; Gazet JC; Sloane JP
J Clin Pathol; 1995 Feb; 48(2):164-7. PubMed ID: 7538149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
